Edition:
United States

Puma Biotechnology Inc (PBYI.N)

PBYI.N on New York Stock Exchange

39.80USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$39.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
167,969
52-wk High
$81.63
52-wk Low
$19.74

PBYI.N

Chart for PBYI.N

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is... (more)

Overall

Beta: 0.44
Market Cap(Mil.): $1,465.36
Shares Outstanding(Mil.): 36.82
Dividend: --
Yield (%): --

Financials

  PBYI.N Industry Sector
P/E (TTM): -- 42.12 30.77
EPS (TTM): -8.16 -- --
ROI: -154.68 -0.81 15.23
ROE: -157.78 -1.52 16.56

BRIEF-Puma Biotechnology Q3 adjusted non-gaap loss per share $1.11

* Puma Biotechnology reports third quarter 2016 financial results

Nov 09 2016

BRIEF-Puma Biotechnology announces underwriters' full exercise of option to purchase additional shares

* Puma Biotechnology announces underwriters' full exercise of option to purchase additional shares

Oct 21 2016

BRIEF-Puma Biotechnology prices public offering of common stock

* Says public offering of 3.75 million common shares priced at $40.00per share

Oct 20 2016

BRIEF-Puma Biotechnology announces proposed public offering of common stock

* Puma Biotechnology announces proposed public offering of common stock

Oct 18 2016

SEC charges former Puma Biotech employee with insider trading

WASHINGTON A former executive for biopharmaceutical company Puma Biotechnology Inc was charged on Thursday by the top U.S. securities regulator and prosecutors with trading on inside information ahead of a company announcement about its breast cancer drug.

Sep 29 2016

UPDATE 1-SEC charges former Puma Biotech employee with insider trading

WASHINGTON, Sept 29 A former executive for biopharmaceutical company Puma Biotechnology Inc was charged on Thursday by the top U.S. securities regulator and prosecutors with trading on inside information ahead of a company announcement about its breast cancer drug.

Sep 29 2016

SEC charges former Puma Biotech employee with insider trading

WASHINGTON, Sept 29 The U.S. Securities and Exchange Commission said on Thursday it had charged a former employee of Puma Biotechnology with insider trading, and that the Justice Department was pursuing a parallel criminal case.

Sep 29 2016

BRIEF-Puma Biotechnology's marketing authorization application for neratinib validated by EMA

* Marketing authorization application for neratinib has been validated by European Medicines Agency Source text (http://bit.ly/2bxvgWa) Further company coverage:

Aug 22 2016

U.S. RESEARCH ROUNDUP-D.R. Horton, Humana, Chicago Bridge & Iron

July 22 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adeptus Health, Chipotle Mexican Grill and Yadkin Financial, on Friday. HIGHLIGHTS * Chicago Bridge & Iron Co : Baird cuts to neutral * D.R. Horton Inc : BofA Merrill cuts to neutral from buy * Humana Inc : Wolfe Research raises to outperform * Community Bank System Inc : Sandler O'Neill cuts to

Jul 22 2016

BRIEF-Puma Biotech applies for marketing approval for breast cancer drug

* Submits NDA for PB272 (neratinib) to U.S. FDA for extended adjuvant treatment of HER2-positive early stage breast cancer Source text for Eikon: Further company coverage:

Jul 21 2016

Earnings vs. Estimates